

HEALTHTRUST®

November 13, 2020

John Young, M.D., MBA Jason Braithwaite, PharmD, MS, BCPS Karen Bush, MSN, FNP, BC, NCRP

COVID-19 | Vaccine Update


Live webinar held 11/13/20; slides updated 12/03/20

Welcome & Introductions

Special thanks to Emily Singleton, PharmD for content assistance



COVID-19 Bad News, Good News



Good News


- Better understanding of disease progression and mitigation strategies
- Transmission related to school attendance
- EUA approval of treatments (convalescent plasma and monoclonal antibodies)
- Early data from Pfizer and BioNTech vaccine is promising
- Moderna results anticipated within weeks


Updated 11/9/2020 2pm


Individual case and death counts excluded for the following: American Samoa; Diamond Princess; Grand Princess; Guam; Northern Mariana Islands; Puerto Rico; and, Virgin Islands. Values included as part of US Total selection.




Average # of New Cases the Last 7 & 14 Days Between School Ages (5–18) & All Ages
















Last 14 days among ages 5-18 Last 14 days among all age


Dickson County





Last 7 Days Ages 5-18 Last 7 Days All Ages Last 14 Days Ages 5-18 Last 14 Days All Ages


Data Sources: Tennessee Department of Health, Epidemiology and Surveillance Data; The COVID Tracking Project; Johns Hopkins University Center for Systems Science and Engineering (CSSE); Harvard Global Health Institute* Key Metrics for COVID Suppression, A Framework for policy makers and the public. July 2020, https://globalepidemics.org/wp-content/uploads/2020/06/key metrics and indicators v4.pdf






Longitudinal Infection Rate Trajectories








The effective reproduction number (or transmission rate) (R_t) by county measures the effective number of people infected by each infected individual at time t under local conditions and practices. Each data point is a 14-day weighted moving average. A transmission rate above a rate of 1.0 signals a spread; a rate below 1.0 signals the spread is slowing.

Data Sources: Tennessee Department of Health, Epidemiology and Surveillance Data; The COVID Tracking Project; Johns Hopkins University Center for Systems Science and Engineering (CSSE); Harvard Global Health Institute* Key Metrics for COVID Suppression, A Framework for policy makers and the public. July 2020, https://globalepidemics.org/wp-content/uploads/2020/06/key_metrics_and_indicators_v4.pdf





Vaccination Facts

INFLUENZA VACCINATION IS STILL IMPORTANT



Influenza Vaccine

CDC burden of influenza averted by vaccination last season showed it prevented:

- 7.5 million flu illnesses
- 3.7 million flu medical visits
- 105,000 flu hospitalizations
- 6,300 flu deaths

2019–2020 vaccination coverage among those 6 months and older increased from last season to nearly 52%



COVID-19 Vaccine

COVID-19 Vaccination availability per DOD briefing on Operation Warp Speed

- 10s of millions by the end of December
- 100s millions by January or February


You can receive the influenza & COVID-19 vaccine in the same visit

References:

Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States 2019-2020 Influenza Season. Available at: https://www.cdc.gov/flu/about/burden-averted/2019-2020.htm US Dept of Defense. This week in Operation Warp Speed, October 16,2020 Briefing. Available at: https://www.defense.gov/Newsroom/Releases/Release/Article/2385035/this-week-in-operation-warp-speed-oct-16-2020/



Operation Warp Speed (OWS)



https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html

IMPORTANT NOTICE: The content in this communication is provided for <u>informational purposes only</u> and intended for its <u>direct recipients</u>. Due to the urgent and dynamic nature of the COVID-19 pandemic, the potential member best practices, experimental techniques, and other materials below may be preliminary, evolving and subject to change. Nothing herein is intended to replace health system practices and independent clinical decision-making, which are the sole responsibility of systems and their practitioners. HealthTrust, on behalf of itself and any members that have provided this content, expressly disclaims any liability for health system operational and treatment decisions.




7

Historical vs. OWS Vaccine Development Process



MISSION: Deliver 300 million doses of safe and effective vaccine by 1 January 2021.



IMPORTANT NOTICE: The content in this communication is provided for informational purposes only and intended for its direct recipients. Due to the urgent and dynamic nature of the COVID-19 pandemic, the potential member best practices, experimental techniques, and other materials below may be preliminary, evolving and subject to change. Nothing herein is intended to replace health system practices and independent clinical decision-making, which are the sole responsibility of systems and their



practitioners. HealthTrust, on behalf of itself and any members that have provided this content, expressly disclaims any liability for health system operational and treatment decisions.

Vaccine Candidates

COVID-19 Candidates in Phase 3 in the U.S.


	BNT162b2	mRNA-1273	AZD1222	Ad26.COV2.S
Manufacturer	Pfizer & BioNTech	Moderna	AstraZeneca & University of Oxford	Janssen
Platform	mRNA	mRNA	Non-Replicating Viral Vector	Non-Replicating Viral Vector
Phase 3 Study Population	43,538 participants enrolledAge 12-85 years	 30,000 participants enrolled Age ≥18 years 	 ~30,000 participants planned Age ≥18 years 	 • ~60,000 participants planned • Age ≥18 years
Dosing	30 mcg/0.3 mL IM, 2 doses 21 days apart	100 mcg/0.5 mL IM, 2 doses 28 days apart	5×10^{10} vp/0.5 mL IM, 2 doses 28 days apart	5 × 10 ¹⁰ vp/0.5 mL IM, 1 dose
How Supplied	Solution for dilution in 5-dose vial	Solution in 10-dose vial	Solution in 10-dose vial	Solution in 5-dose vial
Storage & Stability	 6 months in ultra-low temp freezer at -60 to -80°C 30 days in thermal shipper at -60 to -80°C 5 days in fridge at 2-8 °C After dilution, 6 hours at room temperature 	 6 months in freezer at -20°C 30 days in fridge at 2-8°C 12 hours at room temperature Once entered, 6 hours at room temperature 	 In fridge at 2-8°C 4 hours at room temperature 	 3 months in fridge at 2-8°C Once entered, 6 hours in fridge at 2-8°C
Timeline	Expect to have data required for EUA by 3 rd week of November then submit for EUA	Expect to have data required for EUA in 2 nd half of November then submit for EUA	Expect to have data later this year	To be determined




https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf

Vaccine Candidates' Differing Approaches

U.S. COVID-19 Candidates in Phase 3






Non-Replicating Viral Vector AstraZeneca / Janssen

VIRAL-VECTOR VACCINES

Replicating viral vector (such as weakened measles) The newly approved Ebola vaccine is an example of a viral-vector vaccine that replicates within cells. Such vaccines tend to be safe and provoke a strong immune response. Existing immunity to the vector could blunt the vaccine's effectiveness, however.

Non-replicating viral vector (such as adenovirus)

No licensed vaccines use this method, but they have a long history in gene therapy. Booster shots can be needed to induce long-lasting immunity. US-based drug giant Johnson & Johnson is working on this approach.




https://www.nature.com/articles/s41563-020-0746-0

https://www.nature.com/articles/d41586-020-01221-y



Distribution in a Phased Approach





COVID-19 Vaccine Allocation Decision Framework

H = high risk; M = medium risk; L = low risk

The NIH & CDC requested that the National Academies of Sciences, Engineering & Medicine & the National Academy of Medicine (NAM) develop a framework to assist policymakers' plan for equitable allocation of COVID-19 vaccines




NAM findings from Sept. 1 were shared with the CDC's Advisory Committee on Immunization Practices (ACIP)



https://www.hhs.gov/sites/default/files/strategy-for-distributing-covid-19-vaccine.pdf https://www.nap.edu/catalog/25917/framework-for-equitable-allocation-of-covid-19-vaccine

Phases	Population Group	Criterion 1: Risk of Acquiring Infection	Criterion 2: Risk of Severe Morbidity and Mortality	0	Criterion 4: Risk of Transmitting Infection to Others	Mitigating Factors for Consideration
1a	High-risk health workers	Н	М	Н	Н	Adequate access to personal protective equipment. Workplace management of exposure.
1a	First responders	Н	М	Н	Н	Adequate access to personal protective equipment. Workplace management of exposure.
1b	People with significant comorbid conditions (defined as having two or more)	М	Н	М	М	Ability to maintain social distance and isolate.
1b	Older adults in congregate or overcrowded settings	Н	Н	L	М	Effective institutional management of exposure
2	K–12 teachers and school staff and child care workers	Н	М	Н	Н	Online schooling, especially for lower grades, recognizing educational and social impacts.
2	Critical workers in high- risk settings	Н	М	Н	М	Adequate access to personal protective equipment. Workplace management of exposure.
2	People with moderate comorbid conditions	М	М	М	М	Ability to maintain social distance and isolate.
2	People in homeless shelters or group homes and staff	Н	Н	L	Н	Adequate access to personal protective equipment. Effective institutional/workplace management of exposure.
2	Incarcerated/detained people and staff	Н	М	L	Н	Adequate access to personal protective equipment. Effective institutional/workplace management of exposure.
2	All older adults	М	Н	L	L	Ability to maintain social distance and isolate.
3	Young adults	Н	L	М	Н	Ability to maintain social distance and isolate. Closure of congregate settings (e.g., bars).
3	Children	М	L	М	Н	Ability to participate in online schooling.
3	Workers in industries important to the functioning of society	М	М	М	М	Adequate access to personal protective equipment. Effective institutional/workplace management of exposure.




techniques, and other materials below may be preliminary, evolving and subject to change. Nothing herein is intended to replace health system practices and independent clinical decision-making, which are the sole responsibility of systems and their Health Trust, on behalf of itself and any members that have provided this content, expressly disclaims any liability for health system operational and treatment decisions.



COVID-19 Vaccine Distribution: A Logistical Challenge

- McKesson will be sole distributor for all COVID-19 vaccines with the exception of Pfizer
- Pfizer vaccines will come direct from Pfizer to administration sites
- Ancillary kits will be supplied separately but shipped to match vaccine delivery schedule
- Partner depots (i.e., FedEx, UPS) have freezer farms to hold shipments
- \triangleright Ultra cold chain and two-shot vaccination series complicate the scenarios



OVERVIEW OF DISTRIBUTION AND ADMINISTRATION


https://www.hhs.gov/sites/default/files/strategy-for-distributing-covid-19-vaccine.pdf

IMPORTANT NOTICE: The content in this communication is provided for informational purposes only and intended for its direct recipients. Due to the urgent and dynamic nature of the COVID-19 pandemic, the potential member best practices, experimental

techniques, and other materials below may be preliminary, evolving and subject to change. Nothing herein is intended to replace health system practices and independent clinical decision-making, which are the sole responsibility of systems and their practitioners. 13 HealthTrust, on behalf of itself and any members that have provided this content, expressly disclaims any liability for health system operational and treatment decisions.



Vaccine Administration Supplies



Diluent Kits & Timing of Delivery

Additional Supplies Needed

McKesson Distributed Vaccines For vaccines requiring a diluent to mix, a separate kit with needles, syringes & alcohol pads will be automatically ordered

May be delivered in separate package from vaccine, but arrive on or before vaccine delivery

Pfizer Distributed Vaccines

Combined kit of administration supplies, mixing supplies & vials of diluent will ship together

For all vaccine administration

- Sharps containers
- Exam gloves
- Bandages
- Additional PPE required by hospital policy


For Pfizer vaccine

- Cryogenic gloves
- Dry ice shovel / scoop
- Eye protection

https://www.hhs.gov/sites/default/files/strategy-for-distributing-covid-19-vaccine.pdf



Pfizer Candidate: How Supplied




https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf https://www.pfizer.com/

IMPORTANT NOTICE: The content in this communication is provided for informational purposes only and intended for its direct recipients. Due to the urgent and dynamic nature of the COVID-19 pandemic, the potential member best practices, experimental


15 techniques, and other materials below may be preliminary, evolving and subject to change. Nothing herein is intended to replace health system practices and independent clinical decision-making, which are the sole responsibility of systems and their practitioners. HealthTrust, on behalf of itself and any members that have provided this content, expressly disclaims any liability for health system operational and treatment decisions.



Pfizer Candidate: Storage & Stability



Moderna Candidate: How Supplied & Storage & Stability



https://www.modernatx.com/

IMPORTANT NOTICE: The content in this communication is provided for informational purposes only and intended for its direct recipients. Due to the urgent and dynamic nature of the COVID-19 pandemic, the potential member best practices, experimental

17 techniques, and other materials below may be preliminary, evolving and subject to change. Nothing herein is intended to replace health system practices and independent clinical decision-making, which are the sole responsibility of systems and their practitioners. HealthTrust, on behalf of itself and any members that have provided this content, expressly disclaims any liability for health system operational and treatment decisions.



How We Have Expedited Development

- Prior knowledge of coronaviruses (SARS, MERS)
- Improvement in gene sequencing
- Advancements in bioengineering tech
 - Weakened virus (Flu shots) expensive & time-consuming
 - Spike Proteins (Sanofi, AZ)
 - Viral vector (J&J)
 - Genetic code (Inovio, Pfizer, Moderna) first in class
- Government support & funding
 - \$10 Billion in funding
 - Allows for parallel testing to occur without risk of losing millions
- Shortened testing timeline
 - Cells
 - Animals
 - Human
 - ✓ Phase 1, 2 and 3 done in parallel
 - ✓ Very costly but government funded





COVID-19 Vaccine Safety & Efficacy

Pre-approval 5 checkpoints

19



Post-approval safety monitoring

- Vaccine Adverse Event Reporting System
- Vaccine Safety Datalink
- Clinical Immunization Safety Assessment Project
- FDA and The Centers for Medicare and Medicaid Services
- FDA Biologics Effectiveness and Safety System
- FDA: Sentinel Initiative
- Department of Defense
- Department of Veterans Affairs
- Indian Health Service

Expanded safety monitoring

- CDC: V-SAFE
- CDC National Healthcare Safety Network
- FDA: Other large insurer/payer databases

References:

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety.html https://www.fda.gov/media/139638/download



COVID-19 VACCINE Checklist for Vaccine Preparation 10/29/20

Date	Activity		Additional Resources/Information
	Pre-Vaccine Enro	Ime	nt
	Consider establishing a COVID-Vaccine Coordinator	•	This person will stay abreast of vaccine progress and availability, assist with coordination of operational considerations and ensure appropriate staff education.
	Review jurisdiction COVID-19 Interim Vaccination Plan	•	Internet search jurisdiction name and "COVID-19 Vaccination Plan".
	Check jurisdiction requirements for vaccination enrollment	•	This varies by jurisdiction, check the vaccination plan for details.
	Complete the COVID-19 Program Provider Agreement	•	This form is required by the CDC, but submitted to jurisdiction. Many jurisdiction are creating on line versions of this form for submission. <u>Preview a draft of the</u> <u>agreement</u> .
	Complete the COVID-19 Vaccination Program Provider Profile Form	•	This form is required by the CDC, but submitted to jurisdiction. Many jurisdiction are creating online versions of this form for submission. Information to have available can be located <u>here</u> .
	Consider your capacity to store and administer a	•	Storage, staffing and patient flow.
	two-stage vaccine 21-28 days apart		
	Immunization Informatio	n Sy	/stem (IIS)
	Identify the system the jurisdiction is using to submit vaccination information Confirm facility is enrolled in the system. If not	•	The system utilized varies by jurisdiction. Check your jurisdiction's plan.
	take steps to enroll		
	Request or verify user access for individuals who will be providing vaccines and entering patient information into the IIS		
	Verify if EMR in use will communicate with IIS	1	

Click to download.

Program Planning – Getting Started

Connect with your jurisdiction

- Jurisdictions consist of:
 - 50 states
 - 6 cities (Chicago, Houston, Philadelphia, District of Columbia, New York City & San Antonio)
 - 8 territories (American Samoa, Guam, Marshall Islands, Micronesia, N. Mariana Islands, Palau, Puerto Rico, U.S. Virgin Islands)
 - 1 federal entity Indian Health Services
- Each jurisdiction developed, and submitted for approval, its COVID-19 Vaccination Plan, based on the guidance from the CDC
- Access to executive summaries of these plans is available <u>here</u>
- The HealthTrust Vaccination Checklist

Each location wishing to receive/administer COVID-19 vaccine (point of dispensing) must work with its jurisdiction to complete the Vaccination Provider Enrollment & the CDC COVID-19 Vaccination Provider Profile form for each location where the vaccine will be administered.

<u>References : https://www.cdc.gov/vaccines/covid-19/covid19-vaccination-guidance.html</u> <u>https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim</u> Playbook.pdf



Consider Current Processes for Influenza Vaccination During COVID-19

SIMILARITIES

- Appropriate PPE for vaccine administrators
- Schedule appointments
- Screen for COVID-19 symptoms
- Call from car prior to entering
- Ensure patient flow to avoid congestion prior to and after vaccination
- Maintain social distancing and universal masking

21

DIFFERENCES

- Ordering
- Distribution
- Storage
- Reactogenicity
- Education



Ordering & Distribution



Influenza Vaccine Pull With Open Dispensing

- Order vaccine and it is delivered to the site
- Points of dispensing (POD) are open
- Vaccine can be administered to any patient
- Vaccine is accessible in multiple locations

References:

US Dept of Defense. This week in Operation Warp Speed, October 16,2020 Briefing. Available at:

https://www.defense.gov/Newsroom/Releases/Release/Article/2385035/this-week-in-operation-warp-speed-oct-16-2020/

CDC COVID-19 Vaccination Program Interim Playbook Jurisdiction Operations. Available at:

https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf



COVID-19 Vaccination Push/Closed Distribution

Initial Phases (I/II) of vaccination


- Vaccine is ordered by the jurisdiction through the VTrkS System
- The vaccine is pushed to the jurisdictions as it becomes available
- The jurisdiction allocates the vaccine to predetermined points of dispensing based on specific criteria
 - Jurisdiction Vaccination Plan
 - Advisory Committee for Immunization Practices
 - Sites ability to vaccinate target population
 - POD must file appropriate documents with the jurisdiction
- Vaccine is distributed to a defined population within the POD (closed dispensing)



Storage

Risk of improper storage & security risk

- Each of the COVID-19 vaccines has different storage requirements
- Concerns have been voiced regarding security risk
- Delivery locations should have availability of 24-hour delivery with two points of contact for each location
- Review of standard operating procedures for vaccine delivery and security is recommended
- Ensure all staff are educated as to proper delivery and security procedures
- Staff must be educated on proper storage and handling of each vaccine
 - Dry ice management
 - Viability of vaccine once thawed



References: CDC COVID-19 Vaccination Program Interim Playbook Jurisdiction Operations. Available at: <u>https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf</u> CDC Vaccine Storage and Handling Toolkit Available at : <u>https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf</u>



Reactogenicity – Body's Local & Systemic Response to Vaccine

Safe vaccines can have significant reactogenicity. Note: all injections are likely to cause local pain & tenderness.

Messenger RNA Vaccine	Systemic Reaction Type (mild to moderate)	Timing of Reaction	
Pfizer mRNA	Fever, chills, HA, myalgia, nausea	More significant after second dose	
Moderna mRNA	Chills, HA, myalgia, fatigue	More significant after second dose	
Viral Vectored Vaccine	Systemic Reaction Type (mild to moderate)	Timing of Reaction	
AstraZeneca ChAd Spike	Chills, feverish, HA, malaise, muscle ache	More significant after first dose	
Janssen Ad26 Spike	Fatigue, HA, myalgia, fever	More significant after first dose (within 2 days, lasting 2 days)	
SS-Protein Based	Systemic Reaction Type	Timing of Reaction	
Novavax	Systemic: Fatigue, HA, myalgia, malaise	Single dose vaccine	

MHJ Lifesciences COVID-19 Race for a Vaccine webinar October 27, 2020 Available at: <u>https://www.mjhlifesciences.com/covid/race-for-vaccine</u>



	r								
	ALTHTRUST for & Critical Resources	со	VID-1	.9 Vaco	cine C	Compa	arativ	e Matrix	ĸ
		CO	VID-1	.9 Vaco	cine C	Compa	arativ Distribution	e Matrix	U.S. Commitments
Vaccine	tor & Cinical Resources		Trial Phase	Administration	Number of				U.S.
Vaccine	tor & Chicol Resources solved 10/20/20 Vaccine	Supplier	Trial Phase Status	Administration Route	Number of Doses	How Supplied Likely powder in viat, reconstitute with saline Likely powder in	Distribution	Storage & Stability Currently 2–8°C Planned: • 6 months in ultra-low temperature freezer • 15 days in dry Ice	U.S. Commitments 100 million doses ± 400 million
Vaccine Platform Vill Jaguessaw	Vaccine mRNA-1273	Supplier Moderna	Trial Phase Status Phase 3	Administration Route	Number of Doses	How Supplied Likely powder in viat reconstitute with saline Likely powder in 5-dose viat	Distribution Currently -20°C	Storage & Stability Currently 2–8°C Plarneet. 6 months in ultra-low bengerabare freezer 15 days in dry kee thermat shipper 6 days at 2–8°C • Dikted viai stable at nom tereperature for G	U.S. Commitments 100 million doses ± 400 million doses
Vaccine Platform	Not 3 Official Resources Not 3 Official Resources Not 3 Official Resources MRNA-1273 BNT162b2	Supplier Moderna Pflzer & BioHTech	Trial Phase Status Phase 3 Phase 3	Administration Route M	Number of Doses Likely 2 Likely 2	How Supplied Ukely powder in viał reconstruct with salme Ukely powder in 5-dose viał; reconstruct with salme	Distribution Currently -20°C Likely utra-cold chain Currently cold	Storage & Stability Currently 2-8°C Planned: • 6 months in ultra-low being-colour freezer • 10 Says 12 -95 • Says	U.S. Commitments 100 million doses ± 400 million doses ± 500 million doses ± 500 million
Vaccine Platform	Vice 1 Official Resources Vice 1 Official Resources With 1 Official Resources IMPRING-1273 BINT162b2 Ad26.COV2.5	Sugplier Moderna Pflaer & BioNTech Jahrsion & Johnson AstraZeneca & University	Trial Phase Status Phase 3 Phase 3 Phase 3	Administration Route RM RM	Number of Doses Likely 2 Likely 2 Peteortially 1	How Supplied Usely powder in Vial reconstitute with ualize Likely powder in 5-5dae vial reconstitute with ualize Currently solution in single-vise vial	Distribution Currently -2010 Likely ultra-cold chain Currently cold	Storage & Stability Currently 2–8°C Planned: 4 6 months in site alow thermal hyber 1-5 days it 2–8°C • Object of site alow thermal hyber • Object site alow none temperature for 6 hours Expected to be – 30°C for 2 years or 2–8°C for al months	U.5. Commitments 100 million doses 2 400 million doses 100 million doses 2 500 million doses 100 million doses
Non- Replikating Messenger RNA Viral Vector	Vaccine mRNA-1273 BNT16252 Ad26.COV2.5 A201222	Suppler Moderna Pfizer & BiohTech Jahnuon & Johnson AstraZeneca & Dahmonty	Trial Phase Status Phase 3 Phase 3 Phase 3 Phase 3	Administration Route IM IM IM IM	Number of Doses Likely 2 Likely 2 Potentially 1 Likely 2	How Supplied Usely powder in Viat reconstitute with ualize Likely powder in Sodare Viat Sodare Viat Sodare Viat Sodare Viat Solution in Solution in Vial	Distribution Currently -20°C Likely ultra-cold chain Currently cold chain Currently cold chain	Storage & Stability Currently 2–8°C Planead. 4 6 months in titra-low 15 days in 2–8°C 9 days 22–8°C • Olardo Hoper • Sides 10 days 2–8°C hours Expected to be –30°C for 2 years or 2–8°C for 18 Currently 2–8°C	U.S. Commitments 100 million doses 2 400 million doses 100 million doses 100 million doses 100 million doses 100 million doses 100 million doses



Staff Education

CDC recommended education


- Different vaccines: Storage, administration
- Vaccine development and safety
- Who will receive the vaccine when (Phase Ia, Ib, II, III)
- Currently no vaccination dosages for pediatric patients
- Who is considered a high-risk patient
- Vaccine administration record
- Vaccine adverse event reporting system (VAERS)
- Use of vaccine finder
- Necessary patient education:
 - Vaccine development and safety
 - Vaccinate even if previously COVID-19 positive
 - Two vaccines 21–28 days apart
 - Process for reminder notification
 - EUA process and paperwork
 - Potential side effects

References: CDC COVID-19 Vaccination Program Interim Playbook Jurisdiction Operations. Available at: <u>https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf</u>



Responsible for all vaccine management activities, including an in-depth understanding of the jurisdiction's plan for vaccination

COVID-19 Vaccine Coordinator



RESPONSIBILITIES

- Receive, process and maintain records of inventory
- Ensure acceptable temperature ranges have been maintained during transport
- Maintain proper vaccine storage & monitoring
- Request new inventory
- Maintain list of ordering and vaccinating providers with credentials
- Ensure proper education of staff

CDC COVID-19 Vaccination Program Interim Playbook Jurisdiction Operations. Available at: <u>https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-</u> Program-Interim Playbook.pdf

Vaccine coordinator postinghttps://www.vdh.virginia.gov/content/uploads/sites/11/2016/04/VaccineCoordinator.pdf



HealthTrust Resources

For more COVID-19 Vaccine Resources

https://education.healthtrustpg.com/covid-19-resources/#vaccine-information

HEALTHTRUST'

COVID-19 VACCINE

Checklist for Vaccine Preparation 10/29/20

Date	Activity		Additional Resources/Information
	Pre-Vaccine Enro	Ime	nt
	Consider establishing a COVID-Vaccine Coordinator	•	This person will stay abreast of vaccine progress and availability, assist with coordination of operational considerations and ensure appropriate staff education.
	Review jurisdiction COVID-19 Interim Vaccination Plan	•	Internet search jurisdiction name and "COVID-19 Vaccination Plan".
	Check jurisdiction requirements for vaccination enrollment	•	This varies by jurisdiction, check the vaccination plan for details.
	Complete the COVID-19 Program Provider Agreement	•	This form is required by the CDC, but submitted to jurisdiction. Many jurisdiction are creating on line versions of this form fo submission. <u>Preview a draft of the</u> <u>agreement</u> .
	Complete the COVID-19 Vaccination Program Provider Profile Form	•	This form is required by the CDC, but submitted to jurisdiction. Many jurisdiction are creating online versions of this form for submission. Information to have available can be located here.
	Consider your capacity to store and administer a two-stage vaccine 21-28 days apart	•	Storage, staffing and patient flow.
	Immunization Informatio	n Sy	vstem (IIS)
	Identify the system the jurisdiction is using to submit vaccination information Confirm facility is enrolled in the system. If not take steps to enroll	•	The system utilized varies by jurisdiction. Check your jurisdiction's plan.
	Request or verify user access for individuals who will be providing vaccines and entering patient information into the IIS Verify if EMR in use will communicate with IIS		

COVID-19 Vaccine Comparative Matrix U.S. **Frial Phase** Number of Supplie Status Route Dose) million do vial; mRNA-1273 Moderna Phase 3 Likely 2 Currently 2-8°C ± 400 millio econstitut -20°C doses 5 months in ultraerature freeze 5 days in dry ice 5-dose vial; BNT162b2 Likely 2 Pfizer & BioNTech Phase 3 IM 5 days at 2–8°C ± 500 millio econstitute Diluted vial stable a doses with saline ected to be -20°C fo Currently solution in Ad26.COV2.9 Johnson & Johnson Phase 3 IM ently c vears or 2-8°C for >3 + 200 millio chain months doses single-use vi Rep aZeneca & Unive Currently Currently co 4701222 Phase 3 IM Likely 2 Currently 2-8°C 0 million do of Oxfore . Jution in v chain DNA INO-4800 rio & Beijing Adv Phase 1 ID + EP Likely 2 Not Available art of OWS NVX-CoV2373 Phase 1/2 IM Likely 2 Currently 2-8°C Novavax Solution Not Availa 0 million do million do TRO м Not Available ± 500 million doses Phase 1/2 Likely 1 or 2

HEALTHTRUST

Click to download.

😝 HEALTHTRUST **COVID-19 VACCINE**

PREPARATION – SUPPLIES

Vaccine orders will be approved and transmitted in CDC's Vaccine tracking System (VTrckS) by jurisdiction for each vaccination provider (jurisdictions consist of: 50 states, 8 territories, and 6 large cities). Vaccine (and adjuvant or diluent, if required) will be shipped in quantitie of 100 to provider sites within 48 hours of order approval by the immunization program, if supply is available.

Ancillary supply kits and diluent (if required) will ship separately from the vaccine due to different cold chain requirements, but shipment will be timed to arrive with or before the vaccine

Each Ancilla	ry Kit will have enough supplies to adminis	ter 100 doses of the vaccine, including:						
		served by the ordering vaccination provider)						
	Alcohol prep pads – 210 per kit							
	 Note: Pfizer kits are delivered in quantities of 975 doses. These kits will contain 1 ml syringes because they are small volume vaccines. 							
 Kits that require reconstitution with diluent or mixing adjuvant will include additional necessary syringes, needles and other supplies for this purpose. 								
What is not i	ncluded:	Additional items to consider:						
	s ised jurisdictions to make plans to provide	Some of these vaccines will be delivered in dry ice which will need to be monitored and may need to be replenished. Therefore it is recommended to also consider the following: • Access to dry ice suppliers • Equipment for handling of dry ice • Thermometers for monitoring temperatures						
this informat distribution.	dditional PPE. Some of the jurisdictions have included is information in their individual plans for COVID-19 Note: The Pfizer thermal shippers are supposed to							
	plans for these types of supplies.	 Tracking tool for recording temperatures, sample found here. 						

Click to download.

Click to download.



Upcoming COVID-19 Vaccine Podcast & COVID-19 Collaborative Community



Join our mailing list or Collaborative Community

> **Contact Elle Petty** Elle.Petty@healthtrustpg.com

December 2020 – COVID-19 Vaccine Podcast

- Dr. John Young, CMO, HealthTrust and Dr. Kelly Moore, Founder and President of The Vaccine Advisor, discuss vaccine distribution planning, vaccine prioritization and programs.
- Join our Candid Conversations mailing list for podcast news and updates

COVID-19 Collaborative Community (HealthTrust Members Only)

- Directly connect with peers for collaborative learning in real-time to learn best practices
- Quick and easy access to HealthTrust COVID resources
- Awareness of HealthTrust educational events

